Pulmonx (LUNG) Common Equity (2019 - 2025)

Pulmonx (LUNG) has 7 years of Common Equity data on file, last reported at $54.1 million in Q4 2025.

• Common Equity for Q4 2025 came in at $54.1 million, down 36.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $54.1 million (down 36.93% YoY), and the FY2025 annual result was $54.1 million, down 36.93% from the prior year.
• Common Equity declined to $54.1 million in Q4 2025 per LUNG's latest filing, from $60.0 million in the prior quarter.
• Over five years, Common Equity peaked at $216.1 million in Q1 2021 and troughed at $54.1 million in Q4 2025.
• A 5-year average of $133.4 million and a median of $129.8 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2021 and 2025: Common Equity surged 211.39% in 2021, then sank 36.93% in 2025.
• A 5-year view of Common Equity shows it stood at $193.2 million in 2021, then decreased by 20.3% to $154.0 million in 2022, then dropped by 23.18% to $118.3 million in 2023, then slipped by 27.47% to $85.8 million in 2024, then tumbled by 36.93% to $54.1 million in 2025.
• Business Quant data shows LUNG's Common Equity at $54.1 million in Q4 2025, $60.0 million in Q3 2025, and $69.1 million in Q2 2025.